{"name":"89bio","slug":"89bio","ticker":"ETNB","exchange":"NASDAQ","domain":"89bio.com","description":"89bio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for liver and metabolic diseases. The company's lead product candidate, 89B5, is being developed for the treatment of non-alcoholic steatohepatitis (NASH). 89bio's pipeline also includes other product candidates targeting liver and metabolic diseases. The company is headquartered in San Mateo, California, and its shares are listed on the NASDAQ stock exchange under the ticker symbol ETNB.","hq":"San Francisco, CA","founded":0,"employees":"","ceo":"Rohan Palekar","sector":"Liver / Metabolic Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$850M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":345037000,"netIncome":-367079000,"cash":478685000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"89B5 patent cliff ($0.00 at risk)","drug":"89B5","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BIO89-100","genericName":"BIO89-100","slug":"bio89-100","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BIO89-100","genericName":"BIO89-100","slug":"bio89-100","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"89bio Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"89bio reported its financial results for the fourth quarter and full year 2023, including revenue and net loss.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"trial","headline":"89bio Announces Positive Topline Results from Phase 2a Clinical Trial of 89B5 in NASH","summary":"89bio announced positive topline results from its Phase 2a clinical trial of 89B5 in NASH, demonstrating significant reductions in liver fat and improvements in liver function.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"deal","headline":"89bio Enters into Collaboration and License Agreement with Novo Nordisk","summary":"89bio entered into a collaboration and license agreement with Novo Nordisk to develop and commercialize 89bio's product candidates for the treatment of NASH and other metabolic diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-10-03","type":"pipeline","source":"simplywall.st","summary":"89bio (ETNB): Exploring Valuation After 62% Share Price Surge in the Biotech Sector - simplywall.st","headline":"89bio (ETNB): Exploring Valuation After 62% Share Price Surge in the Biotech Sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQSlhhUEZqVkxmQ21aWUd5V3pmcUVVaU8zemxOZHFDRS1zdjAxVy1zaGk4TTNiMGlHX3d3cGpjWlliNzRXOUtNSEkzazU5ZF9wTW5jRDRvSjhFLUtPU2R0RFl4VnpiUDRyeTVzMTBFY1lFanZSOWxWZ3JTc3NNa1hsNm0xTk8wdU9lTVZaOHNjT2RaLXZNa0dkS0RYRXpDZWJEQ2tBeEVlQzJVVGN0VFRBbDBSMjZVLTNZLXpQLUx0R1BHbmpKVnZSZA?oc=5","date":"2025-09-19","type":"deal","source":"Stocktwits","summary":"89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious - Stocktwits","headline":"89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNYUNxWjlHQ2x4YmJLOHUxSGdMbHhGMEJodUpDZVVQNlNtQmw1bFBLWmJjZHJHbFBuZW9sby1VTm1vQXhVczZhSDFkc2c3bTNTREhoeWNIRjFFandoUEstN1FPay1zUEpXSnhMMjlJOTk2Ui1XYzhJbk1OYmh0aXBPa0F4SWo0OGFKdExOWTFCbFFlaHlJMmtiZVd1YXlEc1JIbnlEZUNCalFsR1VqOHJOOE84Tjl6a1p6WFRVNGtFczVnVmQw?oc=5","date":"2025-09-18","type":"deal","source":"Reuters","summary":"Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters","headline":"Roche to acquire liver drug developer 89bio for up to $3.5 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNbTFmaGVjZDlJaTNyakRoWkhua2tneUdSS1JVXzk5czhiTm5QQjdxSFY1cmZFZ2oyVTZIMkMtUzZUQUdaVl9ZRE1SWktfUjNZYVdmMnMwRHRyTHh1bnpEWktLamItNXlZTmJIUEdPbXRjRllIVkRLUlB2bDBTcjkxV2lR?oc=5","date":"2025-09-18","type":"deal","source":"Seeking Alpha","summary":"Roche deal to buy 89bio boosts MASH space (ETNB:NASDAQ) - Seeking Alpha","headline":"Roche deal to buy 89bio boosts MASH space (ETNB:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNQ0lIaGl3SlVfb1dQeFNSUk9hekxwaHhfRjI0TjVkMTdiTGFVakhqcGpndEY3aGNTZUJDdDZiUHNsT25CeWFUT1hUdW1Wbk82VWJyOXYwSXl3TlgxeUNheWpFdDgwSWZ2ZGVyX2Z4Qmt0bE91aWktQkF0WnZpQzJNbWhOLVNaX1Ftbklv?oc=5","date":"2025-09-18","type":"deal","source":"The Pharma Letter","summary":"Roche punts up to $3.5B to acquire 89bio - The Pharma Letter","headline":"Roche punts up to $3.5B to acquire 89bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYW1KV1lHS2N5b2dQbDdGNElZdHhDdnUtbXlKNVp1UE9OTmtzcVZRRmFMekxiUWVrdUo5OG8waDJwVjRSbTdnZ296YVg1YlZrV0pBYldrLVloYVVVMEEydm9nLXpZaU5ZSUhLM29tN3ViT0l2THZnTGxwbE02U0s2NTdCcFdOZmJYNHNyd3lQOWZJMWNvdl9heTkxaWpyNGJCXzlueF8ydjFMMk0tMmZhRWxFMXRxNHk1bXNV?oc=5","date":"2025-09-18","type":"pipeline","source":"RagingBull","summary":"ETNB Stock Rockets on Roche's Blockbuster Acquisition Announcement – A Biotech Bombshell! - RagingBull","headline":"ETNB Stock Rockets on Roche's Blockbuster Acquisition Announcement – A Biotech Bombshell!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOQlpBNXgtdnlfdUJ4S1dPcWcyejgtaFRHdzdDM3RsYm5EbmlUOElNeGRUMTZqaVFnSWEzcnJkUV9ZMDBRNFBXeVdBNXlzOHFzRE1LbXk1Y2tmSE8wR2xTYk9MQ3RWanpXNV9rSF9nV3FabUczYV9KeEFPZVJFSUwtZk1rcEFDa3lvNkVRYmV3ODIyYjZ1Y21oUkdUdFhwNTl3eWlmdjhRR3RPbUdwUjJYbExNaERUakM2aENNcjJ1V1dpZk1rZzJFVFM4WFpWYXJOX2tIQmlsR2VmMFNQVC0xVEdLbEpRak84VGJOQnRZbXo0YjlVZHh2R2hqWTIyMThkZTBPaXREMVVkRWNiRFkzdk5iTXEyeWV5RE1SZ3JWalBpU1Z5ck9UWW94a1hOMjRRaEE?oc=5","date":"2025-09-18","type":"deal","source":"GlobeNewswire","summary":"Roche enters into a definitive merger agreement to acquire - GlobeNewswire","headline":"Roche enters into a definitive merger agreement to acquire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPVk5zVXY5M3V0YjhUeHRnYlNhSkotOENGVGZmUHlueDdoYWxkZEVTN2lnWC1QOFFFMklHbGJIcmZhRlFONUFRcXZBWFV0Y1dyaFVEVnhlbUs2MHdhSXVzWDJKYkhoZjlRd0QxcW1YSUNYNElQbnA5dGxPMkNLQTBDSllkUWctVUJfblQ1UHZIcFBmdVpELWZSeGdLT24wVGFxRlN6UXlwQ0FucHI3UnRVYWtsaGgzdGRWbVNpYU5R?oc=5","date":"2025-09-18","type":"pipeline","source":"MedCity News","summary":"Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition - MedCity News","headline":"Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-11","type":"regulatory","source":"simplywall.st","summary":"Regulatory Progress and Production Scale-Up Might Change the Case for Investing in 89bio (ETNB) - simplywall.st","headline":"Regulatory Progress and Production Scale-Up Might Change the Case for Investing in 89bio (ETNB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNd2l6bnJBWGFXeVFvLWx2czF3TGJOamNaZFYzMDNQa3pyNzNQemFhNW5JaWlmNy1JUUMzYkNlRWY3akFRUFdpbTF2a25NZjhpV000R1RLQ24wdXR0dVlNd0RxVmRWemxyOWkzR2UtYjBRZ0pqcjhpUTRSbkJIVUUtQnRlaWlkNUF2dEZicjdqaXFmcF9QT0E?oc=5","date":"2024-09-17","type":"regulatory","source":"The Pharma Letter","summary":"Teresa Perney brought in to lead 89bio’s regulatory strategy - The Pharma Letter","headline":"Teresa Perney brought in to lead 89bio’s regulatory strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTkdmNW5KQk5fdDVTWldrRWRXdjRwVzRoNEJ4MTdsM2ppeWRmSmowdnYtV0lkZlVJekZIUG5CU2d1SWNvd1FNUDFSWk02cXZ3RHpBVW5Oai1UNTVISjZmMmp2RHhaRjFEOTVEbDV5QS00QWpHX1V2UGhnUTZvN255YXJtVXVyN3FRcF9kQW53a1h3cHRB?oc=5","date":"2023-11-27","type":"trial","source":"The Pharma Letter","summary":"New long-term data for 89bio’s NASH candidate - The Pharma Letter","headline":"New long-term data for 89bio’s NASH candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOFgxaGlXU0JaWUpadS1fb21CWU9vbnUtS2V4dDFiRVF2RW1NRWpqTHNIb2VJdy1kajZqdXBmbjl1VDlObUtqWjdPSU93SFJvREpMa3R3akphMC1KUHpBN2lLLTJzTDN4bGhvQ3lDRVBCbTZZLTVzUWd1VXItNlI5Sk1XeXJrUGIxOExmNjk2OUNlQQ?oc=5","date":"2023-03-22","type":"pipeline","source":"The Pharma Letter","summary":"89bio latest to offer encouragement in NASH - The Pharma Letter","headline":"89bio latest to offer encouragement in NASH","sentiment":"neutral"}],"patents":[{"drugName":"89B5","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Novo Nordisk","Madrigal Pharmaceuticals"],"therapeuticFocus":["Liver Disease","Metabolic Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":345037000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-367079000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":478685000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}